Combination of FLT3 inhibitors with compounds targeting the STAT pathway or survivin may represent a therapeutic strategy to minimize resistance or re-sensitize resistant cells to FLT3 inhibitors in AML patients with FLT3-ITD mutation. This evidence concerns the gene BIRC5 and acute myeloid leukemia.